Read article Where this chronic myeloid leukaemia information comes from
On this page are the major sources of information that we use to put together this section of CancerHelp UK.
All our information is checked by cancer specialists and surgeons who specialise in treating cancer. The names of our specialist reviewers are at the end of this list. We also try to find patients to review all our sections. If you have had chronic myeloid leukaemia, live in the UK and would like to become a patient reviewer, you can write to us by clicking on contact us.
Cancer Research UK
CancerStats Series
US National Cancer Institute
Information on the treatment of chronic myeloid leukaemia
http://www.cancer.gov/cancertopics/pdq/treatment/CML/Patient
Principles and practice of oncology (8th edition)
De Vita, V.T., Hellman, S. and Rosenberg S.A.
Lippincott, Williams and Wilkins, 2008.
Cancer and its management (5th edition)
Souhami R and Tobias J
Blackwell, 2005
Referral for suspected cancer. A clinical practice guideline.
National Institute for Health and Clinical Excellence (NICE), June 2005
Link to the referral guidelines on the NICE website
Improving outcomes in haematological cancers
National Institute for Health and Clinical Excellence (NICE), October 2003
Link to NICE haematological cancers manual
Imatinib for chronic myeloid leukaemia
National Institute for Health and Clinical Excellence (NICE), October 2003
Link to imatinib guidance on NICE website
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance
National Institute for Health and Clinical Excellence (NICE), August 2011, TA70
Link to guidance on NICE website
Recommendations for the management of BCR/ABL positive chronic myeloid leukaemia.
Goldman J, British Committee for Standards in Haematology, July 2007.
Scottish Medicines Consortium (SMC) Advice
Link to SMC advice on approval for use of nilotinib for newly diagnosed Philadelphia chromosome positive adult patients in chronic phase.
Dasaitinib as first treatment for Philadelphia chromosome positive (Ph+) chronic CML
All Wales Medicines Strategy Group (AWMSG), Advice No: 1211, September 2011
Link to guidance on AWMSG website
Monitoring treatment of chronic myeloid leukaemia. Baccarani M et al. Haematologica, 2008, volume 93, issue 2, pp161-9
Imatinib treatment for chronic myeloid leukaemia: where do we go now? Cortes JE. Journal of Clinical Oncology, 2008, volume 26, issue 20, p3308.
Favourable long term follow up results over 6 years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukaemia after failure of interferon alpha treatment. Hochhaus A et al. Blood, 2008, volume 111, issue 3, p1039.
Updated estimate of survival and cost effectiveness for imatinib vs interferon alpha plus low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukaemia. Reed SD et al. Pharmacoeconomics, 2008, volume 26, issue 5, pp435-46.
Current role of stem cell transplantation in chronic myeloid leukaemia. Gratwohl, A, Prof,. Dr.med, Heim, D PD, Dr. med, Best Practice & Research Clinical Haematology, 2009,22 pp431-443
Dr Nilima Parry-Jones
Dr Prem Mahendra
Dee MCLean – McDee Art, Medical Illustration
- Share this: Tweet
-
-
- Print this page
-
Email this page
Increase text size
Decrease text size
Print page
Print basket
Save pages here and print in one go
Nurse helpline
Questions about cancer? Call freephone
0808 800 4040
or email us
